White Pine Capital LLC purchased a new position in shares of RadNet, Inc. (NASDAQ:RDNT – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 35,709 shares of the medical research company’s stock, valued at approximately $2,462,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bessemer Group Inc. grew its stake in shares of RadNet by 19.3% during the third quarter. Bessemer Group Inc. now owns 474,120 shares of the medical research company’s stock valued at $32,684,000 after acquiring an additional 76,737 shares in the last quarter. Hantz Financial Services Inc. lifted its stake in shares of RadNet by 18.8% in the third quarter. Hantz Financial Services Inc. now owns 872 shares of the medical research company’s stock worth $60,000 after acquiring an additional 138 shares in the last quarter. Diversified Trust Co purchased a new position in RadNet in the third quarter valued at about $361,000. Maryland State Retirement & Pension System boosted its holdings in RadNet by 52.9% in the third quarter. Maryland State Retirement & Pension System now owns 15,742 shares of the medical research company’s stock valued at $1,085,000 after purchasing an additional 5,449 shares during the last quarter. Finally, Lisanti Capital Growth LLC purchased a new position in RadNet in the third quarter valued at about $2,342,000. Hedge funds and other institutional investors own 77.90% of the company’s stock.
Insider Transactions at RadNet
In other RadNet news, EVP Mital Patel sold 44,661 shares of the company’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $78.51, for a total transaction of $3,506,335.11. Following the sale, the executive vice president owned 155,514 shares in the company, valued at $12,209,404.14. This represents a 22.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 5.14% of the stock is owned by insiders.
RadNet Stock Performance
Shares of RadNet stock opened at $76.42 on Monday. The firm has a market cap of $6.02 billion, a PE ratio of -263.52 and a beta of 1.42. The firm’s 50-day simple moving average is $72.78 and its 200-day simple moving average is $65.51. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.49 and a current ratio of 1.49. RadNet, Inc. has a 1 year low of $50.82 and a 1 year high of $85.84.
RadNet (NASDAQ:RDNT – Get Free Report) last issued its quarterly earnings results on Sunday, November 8th. The medical research company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.22 by $0.08. The business had revenue of $638.26 million for the quarter, compared to analysts’ expectations of $639.97 million. RadNet had a negative net margin of 0.94% and a positive return on equity of 3.14%. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.20 earnings per share. Equities analysts forecast that RadNet, Inc. will post 0.56 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
RDNT has been the subject of a number of recent analyst reports. Zacks Research lowered RadNet from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 9th. Truist Financial upped their target price on RadNet from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. KeyCorp upped their target price on RadNet from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, November 10th. Barclays increased their target price on RadNet from $65.00 to $79.00 and gave the company an “overweight” rating in a research note on Friday, August 28th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of RadNet in a research report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $89.67.
View Our Latest Stock Report on RDNT
RadNet Profile
RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.
Featured Articles
- Five stocks we like better than RadNet
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding RDNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RadNet, Inc. (NASDAQ:RDNT – Free Report).
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.
